Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript

Auvelity is annualizing just north of $600M at year-end in its third full year since a 2022 launch, with management saying the product is outpacing peers. The commercial footprint expanded from a 160-person field force to 260 in 2024 and 300 in 2025, market access has improved to ~86% coverage, and the company plans additional expansion in 2026—actions that should support continued script and revenue growth.

Analysis

Auvelity’s commercial momentum masks two divergent margin paths: scale-driven gross profit expansion if utilization stays broad, versus contracting net realized price if PBMs force deeper rebates and step edits. Operationally, continued expansion of the sales footprint will buy share only while reps generate incremental scripts at acceptable ROI; past a point each additional rep has sharply diminishing marginal script lift and raises SG&A elasticity to sales growth, pressuring operating leverage within 6–18 months.

Second-order winners from sustained uptake are specialty pharmacies and data vendors that capture persistently high-margin maintenance scripts and real-world-evidence contracts; losers are incumbent oral antidepressant generics that lose refill share and low-touch scripts. Major catalysts that will re-rate the stock are (1) new payer policies or significant formulary edits (timing: weeks–quarters), (2) RWE showing durable remission (months), and (3) any patent or litigation developments that change exclusivity timelines (quarters–years).

Tail risks are binary and asymmetrical: a safety/regulatory signal or a coordinated PBM reimbursement squeeze can halve revenue expectations within months, while upside levers (label expansion or successful cost-per-remission contracting with payers) compound revenue with multi-year durability. That asymmetry argues for option-structured exposure or calibrated equity size; the high conviction trade is time-boxed (6–18 months) to capture payer behavior and early RWE without being exposed to late-cycle generic risk several years out.

Key Decisions for Investors

• Buy AXSM equity (size 1–2% NAV): horizon 6–12 months. Rationale: capture continued adoption and RWE-driven re-rating. Risk/manage: hard stop at -30% from entry; take-profit tranche at +35–50%.
• Buy AXSM Jan-2027 call spread (buy 1x ~0.65–0.75 delta call, sell 1x ~0.30–0.40 delta call) sized at 0.5–1.0% NAV: max loss = premium, asymmetric upside if uptake/RWE outperforms over 9–12 months. Use spread to cap cost vs naked calls and retain substantial upside if payers remain stable.
• If long equity, hedge with a 3–6 month put or sell near-term covered calls representing ~25% of position to harvest premium while waiting for payer clarity; alternative is a collar to limit downside to ~30% while capping upside to ~40% — appropriate if you expect short-term volatility around quarterly results or payer announcements.